Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Respiratory Aspiration 3Neoplasms 3Neurofibromatosis 1 2Lung Neoplasms 2Postoperative Complications 1Postoperative Cognitive Complications 1Lymphoma, Follicular 1Delirium 1Carcinoma, Non-Small-Cell Lung 1Acute Lung Injury 1

Interventions

Carboplatin 779Pemetrexed 606Cisplatin 543Paclitaxel 490pembrolizumab 461Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 255Nivolumab 244Bevacizumab 233osimertinib 177Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 131Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 93Ipilimumab 86Magnetic Resonance Spectroscopy 83Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Inhalation × Clear all
NCT06896890 2025-03-26

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Inhatarget Therapeutics

Phase 1/2 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡